11/25/21, 6:00 AM RePORT > RePORTER

Back to Search Results

Description

Details

Sub-Projects

Publications

Patents

Outcomes

Clinical Studies

News and More

(L) History

🦙 <u>Similar Projects</u>

Mechanisms of viral proteases in coronavirus replication and pathogenesis

Project Number Contact PI/Project Leader 5R01Al085089-10 BAKER, SUSAN C.Other PIs

Awardee Organization
LOYOLA UNIVERSITY CHICAGO

O. Ollare ▲



Abstract Text

DESCRIPTION (provided by applicant): The goal of our research is to determine how viral proteases function in the replication and pathogenesis of coronaviruses (CoVs). CoVs are a family of positive strand RNA viruses and include Severe Acute Respiratory Syndrome (SARS) CoV and Middle East Respiratory Syndrome (MERS) CoV which are significant human pathogens with pandemic potential. Previously, we dissected the multifunctional nature of CoV papain-like proteases (PLPs) and found that CoV PLPs cleave the viral replicase polyprotein, act as deubiquitinases (DUBs) and delSGylases (delSGs) by removing ubiquitin (Ub) or ISG15 conjugated to lysine residues on proteins, and that PLPs can antagonize the innate immune response, likely by deubiquitylating signaling molecules. Using detailed biochemical and PLP-Ub co-crystal structural analysis, we identified residues within CoV PLPs that differentially affec enzymatic activity in vitro and in cell-based assays. Our initial studies were performed using SARS-CoV PLpro. Here we provide preliminary in vitro and structural data demonstrating that these results can be extended to the BSL-2 model coronavirus mouse hepatitis virus (MHV-A59) papainlike protease. We hypothesize that multifunctional PLP/DUB activity contributes to viral pathogenesis and that selectively disrupting DUB activity will allow activation of innate immunity and reduced viral pathogenesis. To test this hypothesis, we will determine if a modified PLP/DUB enzymatic activity alters viral replication, innate immune response or pathogenesis. We will use reverse genetics to generate murine CoVs encoding PLPs with distinct enzymatic profiles such as DUB deficient, delSGylation deficient, or hyperactive protease. These novel viruses will be evaluated in cell culture and in mice for kinetics of viral RNA synthesis, production of infectious virus, and kinetics of activation of innate immune responses. To extend these studies to other CoVs, we will determine the enzymatic profile (EP) and enzymatic fingerprint (EF) of alpha- and beta-CoV papain-like proteases including bat CoV PLPs. We will express the PLP domain from 10 different CoV species and determine the peptide cleavage activity, deubiquitinating activity, delSGylating activity, and lysine-linkage preferences for each enzyme. With this profile in hand, we will use existing and new X-ray structures combined to guide mutagenesis experiments to differentially disrupt DUB activity and identify the fingerprint associated with reduced DUB activity. We will also determine the role of differential activity in regulating the innate immune response in bat cells. Also, we identified an interaction of the CoV ADP-ribose-1"-phosphatase (ADRP) domain with PLP and we will determine the effect of modifying this interaction on enzymatic activity, viral replication and pathogenesis. These studies will reveal new information on viral protease/DUB activity that will be useful for designing antiviral therapies and vaccines for coronaviruses and other protease/DUB-encoding viruses.

Public Health Relevance Statement

PUBLIC HEALTH RELEVANCE: Coronaviruses can emerge from animal reservoirs and infect humans resulting in outbreaks of pneumonia, such as Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). We want to identify how coronaviruses evade the early warning system of the immune response. These studies will teach us how coronaviruses, and potentially other viruses, slip under the radar of our immune defenses and cause disease.

NIH Spending Category

Biodefense Emerging Infectious Diseases Infectious Diseases Rare Diseases

Project Terms

Adenosine Diphosphate Ribose Affect Amino Acid Sequence Animals Antiviral Agents **Antiviral Therapy Attenuated Biochemical Biological Assay Body Weight decreased** C57BL/6 Mouse **Cell Culture Techniques** Cells Chiroptera Cleaved cell Coronavirus Crystallization **Disease Disease Outbreaks Family** Data **Enzymes** FDA approved **Fingerprint Funding** Goals Hand Health Human Hyperactive behavior ISG15 gene Intervention In Vitro **Innate Immune Response Immune** Immune response Immune system **Kinetics** Modeling Lysine Middle East Respiratory Syndrome Coronavirus Monitor Liver **Natural Immunity** Murine hepatitis virus Mutagenesis **Nature** Mus Mutate Mutation

Read More



11/25/21, 6:00 AM RePORT) RePORTER

∢ Back to Search Results

Description

Details

Sub-Projects

Publications

Patents

Outcomes

Clinical Studies

News and More

<u> History</u>

Similar Projects

Mechanisms of viral proteases in coronavirus replication and pathogenesis

Project Number Contact PI/Project Leader 5R01AI085089-10 BAKER, SUSAN C.<u>Other PIs</u>

sbaker1@luc.edu

Organization

Name Department Type State Code LOYOLA UNIVERSITY CHICAGO MICROBIOLOGY/IMMUN/VIROLOGY IL

City Organization Type Congressional District
MAYWOOD SCHOOLS OF MEDICINE 07

Country

UNITED STATES (US)

Other Information

FOA Administering Institutes or Centers 01-July-2010 **Project Start NATIONAL INSTITUTE OF ALLERGY** PA-13-302 Date AND INFECTIOUS DISEASES Study Section Project End Date 30-June-2022 Special Emphasis Panel ZRG1-IDM-**DUNS Number** CFDA Code <u>B(02)M]</u> 791277940 855 **Budget Start** 01-July-2019

Fiscal Year Award Notice Date 2019 19-June-2019

7**/940 855** Budg Date

Budget End Date 30-June-2022

Awardee Organization

LOYOLA UNIVERSITY CHICAGO

Project Funding Information for 2019

Total Funding Direct Costs Indirect Costs \$705,182 \$562,754 \$142,428

 Year
 Funding IC
 FY Total Cost by IC

 2019
 NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
 \$705,182

NIH Categorical Spending

Click here for more information on NIH Categorical Spending

Funding IC	FY Total Cost by IC	NIH Spending Category
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES	\$705,182	Biodefense; Emerging Infectious Diseases; Infectious Diseases; Rare Diseases;

品 Sub Projects

No Sub Projects information available for 5R01AI085089-10

Publications

No Publications available for 5R01Al085089-10

∀ Patents

No Patents information available for 5R01Al085089-10

Outcomes

The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.

11/25/21, 6:00 AM RePORT) RePORTER

∢ Back to Search Results

Description

Details

Publications

Sub-Projects

Patents

Outcomes

News and More

Clinical Studies

<u>History</u>

Similar Projects

Mechanisms of viral proteases in coronavirus replication and pathogenesis

Project Number Contact PI/Project Leader 5R01AI085089-10 **BAKER, SUSAN C.**Other Pls **Awardee Organization LOYOLA UNIVERSITY CHICAGO**

No Clinical Studies information available for 5R01Al085089-10

News and More

Related News Releases

No news release information available for 5R01Al085089-10

(History

No Historical information available for 5R01Al085089-10

Similar Projects

No Similar Projects information available for 5R01Al085089-10